Log In
Print this Print this

ID-LV305, LV305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionLentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors that express cancer/testis antigen 1B (CTAG1B; NY-ESO-1)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today